NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

Sure.

Problems start with the basic factor that the version of the patent that could be approved is so narrow it does not even cover -L or the UCLA ATL-DC variant. It requires IL-11(?) to be used in the maturation and neither NWBO nor UCLA do so.

The other version would cover current combo trial, but is still being objected to as obvious based on other's work.

Then there is also the issue of the multiple assignees. What that means is any of them can give permission to use it. UCLA will presumably assign rights to NCI and that will not be an issue. But CRL and Revimune are separate companies that anybody could come to and get a license. That is, if the patent is ever issued.

Further, the patent only covers gliomas. It does not cover other cancers.